{"id":264584,"date":"2024-05-20T00:00:00","date_gmt":"2024-05-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/cutron0017-2024-biopharma-acute-myeloid-leukemia-current-treatment\/"},"modified":"2026-03-31T10:30:05","modified_gmt":"2026-03-31T10:30:05","slug":"cutron0017-2024-biopharma-acute-myeloid-leukemia-current-treatment-current-treatment-physician-insights","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0017-2024-biopharma-acute-myeloid-leukemia-current-treatment-current-treatment-physician-insights\/","title":{"rendered":"Acute Myeloid Leukemia &#8211; Current Treatment &#8211; Current Treatment: Physician Insights"},"content":{"rendered":"<p>Acute myeloid leukemia (<abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr>) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing shift toward the use of targeted therapies. Their approval has broadened the current treatment arsenal, which now includes the CD33-targeting antibody-drug conjugate Mylotarg (Pfizer), the <abbr title=\"B-cell lymphoma\">BCL<\/abbr>-2-targeting agent Venclexta (AbbVie \/ Genentech), the <abbr data-abbreviation-entity=\"5933\" title=\"Sonic hedgehog\u00a0\">SHH<\/abbr> inhibitor Daurismo (Pfizer), and the <abbr data-abbreviation-entity=\"7627\" title=\"isocitrate dehydrogenase 2\">IDH2<\/abbr> inhibitor Idhifa (Servier \/ Bristol Myers Squibb). In July 2023, the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> approved Daiichi Sankyo\u2019s Vanflyta for <abbr data-abbreviation-entity=\"7629\" title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr>-mutation-positive <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr>. It now competes directly with Rydapt (Novartis) in the newly diagnosed intensive induction setting. Additionally, the December 2022 approval of the <abbr data-abbreviation-entity=\"8653\" title=\"isocitrate dehydrogenase 1\">IDH1<\/abbr> inhibitor Rezlidhia (Rigel Pharmaceuticals) has had an impact on the market through its direct competition with Tibsovo (Servier) in the relapsed\/refractory (<abbr title=\"relapsed\/refractory\">R\/R<\/abbr>) setting.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How has the entry of Vanflyta and Rezlidhia affected surveyed hematologist-oncologists\u2019 prescribing decisions?<\/li>\n<li>How does physician prescribing of current treatments vary based on genetic mutation?<\/li>\n<li>How do drug-treatment rates vary across <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> settings?<\/li>\n<li>What are the main obstacles to prescribing Tibsovo, Idhifa, and Rezlidhia for <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> with <abbr data-abbreviation-entity=\"8144\" title=\"isocitrate dehydrogenase\">IDH<\/abbr>1\/2 mutations?<\/li>\n<li>What are the key prescribing drivers and obstacles facing therapies such as Vyxeos and Onureg?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand uses that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><b>Markets covered: <\/b>United States<\/p>\n<p><b>Primary research: <\/b>Survey of 100 U.S. hematologist-oncologists<\/p>\n<p><b>Key drugs covered: <\/b>Daurismo, Idhifa, Mylotarg, Onureg, Rezlidhia, Rydapt, Tibsovo, Vanflyta, Venetoclax, Vyxeos, Xospata<\/p>\n","protected":false},"template":"","class_list":["post-264584","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-current-treatment","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/264584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/264584\/revisions"}],"predecessor-version":[{"id":281001,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/264584\/revisions\/281001"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=264584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}